Every 8-K that ResMed Inc. (RMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMD filings page.
ResMed Inc. (RMD) announced that it entered into an accelerated share repurchase (ASR) agreement with Citibank, N.A. to repurchase $450.0 million of its common stock. The ASR is conducted under a board-approved repurchase authorization for 20,000,000 shares of common stock originally approved in February 2014.
ResMed intends to fund the ASR using proceeds from the sale of its MatrixCare business and cash on hand. On September 3, 2026, ResMed will pay Citibank $450.0 million and expects an initial delivery of shares equal to 80% of $450.0 million divided by the closing price of its common stock on September 2, 2026. The final number of shares repurchased will be determined based on the average daily volume weighted average price of the stock during the ASR term, less a discount and subject to adjustments. Final settlement is scheduled for December 2026, although Citibank may elect to complete it earlier under the agreement’s terms.
ResMed Inc. reported board and auditor changes. On August 13, 2026, the Audit Committee dismissed KPMG as independent registered public accounting firm and selected PricewaterhouseCoopers LLP (PwC), subject to completion of PwC’s standard client acceptance procedures, for the fiscal year ending June 30, 2027. KPMG’s audit reports for the fiscal years ended June 30, 2026 and 2025 contained no adverse opinions, disclaimers, or qualifications, and ResMed states there were no disagreements or reportable events with KPMG. The company also states it did not consult PwC on accounting or auditing matters during these periods. Director Ronald Taylor informed the Board he will not stand for election at the 2026 annual meeting, expected on November 18, 2026, and will retire at that time. The Board approved Carol Burt as lead director effective November 15, 2026, and these governance changes were announced in a press release furnished as an exhibit.
ResMed Inc. reported higher sales and earnings for the quarter and fiscal year ended June 30, 2026, and announced a larger dividend. For the fourth quarter, revenue was $1,464 million, up 9% from $1,348 million. GAAP diluted EPS was $2.64 versus $2.58, while non-GAAP diluted EPS rose to $2.95 from $2.55. GAAP gross margin declined to 58.8% from 60.8%, reflecting items such as $41.9 million of Astral field safety notification expenses, but non-GAAP gross margin improved to 62.3% from 61.4%.
For fiscal 2026, revenue reached $5,653 million, a 10% increase year over year. GAAP diluted EPS was $10.43 versus $9.51, and non-GAAP diluted EPS increased to $11.17 from $9.55, as operating margin expanded to 33.4% and non-GAAP operating margin to 36.1%. Operating cash flow for the year was $1,806 million. The board declared a quarterly cash dividend of $0.66 per share, a 10% increase, with a record date of August 20, 2026 and payment on September 24, 2026; holders of CHESS Depositary Interests on the ASX will receive an equivalent amount based on the 10:1 CDI-to-share ratio.
ResMed is reshaping its portfolio by agreeing to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, with closing expected in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions. MatrixCare generated about $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026.
ResMed plans to use net proceeds to return capital to shareholders, including via an accelerated share repurchase program, and for general corporate purposes. Transition services agreements are expected to largely offset first-year stranded costs. The company also notes its Noctrix acquisition should add roughly $30 million of revenue in fiscal 2027 but reduce non-GAAP diluted EPS by about $0.20, while it reiterates its fiscal 2026 outlook and targets high single-digit revenue growth with operating leverage in its Residential Care Software segment in fiscal 2027.
ResMed Inc. announced a planned chief financial officer transition. Long‑tenured CFO Brett Sandercock will retire from the CFO role effective May 4, 2026 and move into special advisory positions to support Chairman and CEO Mick Farrell during the leadership handover.
The company appointed Aaron Bloomer, formerly CFO of Exact Sciences, as the new Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 4, 2026. His package includes a $725,000 base salary, a $150,000 sign‑on bonus, and a $3.3 million sign‑on equity grant split between restricted stock units and performance stock units.
ResMed also reported third‑quarter fiscal 2026 results and reiterated its fiscal 2026 outlook, including a gross margin range of 62–63%, SG&A expenses of 19–20%, R&D expenses of 6–7%, and an effective tax rate of 21–23%.
ResMed Inc. reported strong third-quarter fiscal 2026 results and declared a cash dividend. Net revenue was $1.43 billion, up 11% from $1.29 billion a year earlier, with GAAP net income of $398.7 million and diluted EPS of $2.74.
Non-GAAP diluted EPS was $2.86, up from $2.37. Operating cash flow for the quarter was $554.1 million, and cash and cash equivalents were $1.66 billion as of March 31, 2026. The board declared a quarterly dividend of $0.60 per share, with a record date of May 14, 2026 and payment on June 18, 2026.
ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.
ResMed Inc. reported the results of its 2025 annual meeting of stockholders. Director Richard Sulpizio did not seek re-election, and his term ended at the close of the meeting. The board then reduced its size from twelve to eleven members, with stockholders electing eleven directors to serve until the 2026 annual meeting.
Stockholders approved several key proposals. They ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers. They also approved an amendment and restatement of the 2009 Incentive Award Plan, increasing the shares reserved for issuance by 2,400,000, eliminating the plan’s fixed term, and authorizing incentive stock options. In addition, they approved an amendment and restatement of the 2018 Employee Stock Purchase Plan, increasing its share reserve by 3,000,000, removing its fixed term, and providing for tax-qualified purchase rights under Section 423 of the Internal Revenue Code.
ResMed Inc. (RMD) declared a quarterly cash dividend of US $0.60 per share. The dividend has a record date of November 13, 2025 and is payable on December 18, 2025. The ex-dividend date is November 12, 2025 for both NYSE common stockholders and ASX CDI holders. Payments will be made in U.S. dollars to NYSE holders, while ASX CDI holders will receive an equivalent amount in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 CDI-to-NYSE share ratio.
ResMed also noted an ASX waiver allowing it to defer processing share-to-CDI conversions from November 12–13, 2025. Additionally, the company furnished a press release describing results for the quarter ended September 30, 2025.
ResMed Inc. has appointed Nicole Mowad-Nassar to its board of directors, effective immediately, with her initial term running until the November 19, 2025 annual meeting, unless it ends earlier. She serves as senior vice president and president of specialty and U.S. therapeutics operations at AbbVie Inc.
Mowad-Nassar will join ResMed’s Compensation and Leadership Development Committee and receive non-executive director compensation under the company’s standard director program, including a cash retainer of $75,000 for fiscal 2026. ResMed will also enter into its customary indemnification agreement with her.
Director Richard Sulpizio has informed the company that he will not stand for re-election and intends to retire from the board at the 2025 annual meeting, anticipated on November 19, 2025. His decision is stated not to result from any disagreement with ResMed’s operations, policies, or practices.